MARKET

ORKA

ORKA

Oruka Therapeutics Inc
NASDAQ
44.75
+0.27
+0.60%
Opening 14:10 03/30 EDT
OPEN
44.53
PREV CLOSE
44.48
HIGH
45.78
LOW
43.50
VOLUME
415.99K
TURNOVER
--
52 WEEK HIGH
47.25
52 WEEK LOW
5.49
MARKET CAP
2.22B
P/E (TTM)
-19.3584
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ORKA last week (0323-0327)?
Weekly Report · 9h ago
ORUKA THERAPEUTICS INC <ORKA.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $109 FROM $86
Reuters · 4d ago
U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop
Reuters · 4d ago
Piper Sandler Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
TipRanks · 6d ago
Weekly Report: what happened at ORKA last week (0316-0320)?
Weekly Report · 03/23 09:01
Oruka Therapeutics Insiders Make Eye-Catching Stock Moves
TipRanks · 03/18 02:03
Oruka Therapeutics Is Maintained at Outperform by Leerink Partners
Dow Jones · 03/16 19:04
Oruka Therapeutics Price Target Raised to $86.00/Share From $58.00 by Leerink Partners
Dow Jones · 03/16 19:04
More
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Webull offers Oruka Therapeutics Inc stock information, including NASDAQ: ORKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORKA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORKA stock methods without spending real money on the virtual paper trading platform.